The antiviral activity and mechanism of action of (S)-[3-hydroxy-2-(phosphonomethoxy)propyl] (HPMP) nucleosides

Antiviral Research

Volumn 96, Issue 2, 2012, Pages 169-180

  Magee, Wendy C ^a   Evans, David H ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

DNA polymerase; HPMP nucleoside; Nucleotide analog; Reverse transcriptase

Indexed keywords

9 (3 HYDROXY 2 PHOSPHONOMETHOXYPROPYL)NUCLEOSIDE; ACYCLIC NUCLEOSIDE; ACYCLIC NUCLEOSIDE PHOSPHONATE; DEOXYADENOSINE TRIPHOSPHATE; DEOXYCYTIDINE TRIPHOSPHATE; DNA POLYMERASE; NUCLEOTIDE DERIVATIVE; RNA DIRECTED DNA POLYMERASE; RNA POLYMERASE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; DENGUE VIRUS; DNA VIRUS; DRUG METABOLISM; GENE REPLICATION; HOST CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; INFLUENZA VIRUS; METABOLITE; NONHUMAN; PAPILLOMA VIRUS; POLYOMA VIRUS; PREDICTION; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; RNA VIRUS; VIRUS GENOME;

ANTIVIRAL AGENTS; DNA VIRUSES; DNA-DIRECTED DNA POLYMERASE; DNA-DIRECTED RNA POLYMERASES; HUMANS; NUCLEOSIDES; ORGANOPHOSPHONATES; RNA VIRUSES; VIRUS REPLICATION;

DENGUE VIRUS; DNA VIRUSES; HUMAN HERPESVIRUS 5; HUMAN IMMUNODEFICIENCY VIRUS 1; ORTHOMYXOVIRIDAE; PAPILLOMAVIRIDAE; POLYOMAVIRUS; RESPIRATORY SYNCYTIAL VIRUS; RNA VIRUSES; VACCINIA VIRUS;

EID: 84867236118     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2012.08.010     Document Type: Review

References (120)

1. Aduma P., Connelly M.C., Srinivas R.V., Fridland A. Metabolic diversity and antiviral activities of acyclic nucleoside phosphonates. Mol. Pharmacol. 1995, 47:816-822.
2. Aldern K.A., Ciesla S.L., Winegarden K.L., Hostetler K.Y. Increased antiviral activity of 1-O-hexadecyloxypropyl-[2-(14)C]cidofovir in MRC-5 human lung fibroblasts is explained by unique cellular uptake and metabolism. Mol. Pharmacol. 2003, 63:678-681.
3. Andrei G., Snoeck R., Reymen D., Liesnard C., Goubau P., Desmyter J., De Clercq E. Comparative activity of selected antiviral compounds against clinical isolates of varicella-zoster virus. Eur. J. Clin. Microbiol. Infect. Dis. 1995, 14:318-329.
4. Andrei G., Snoeck R., Vandeputte M., De Clercq E. Activities of various compounds against murine and primate polyomaviruses. Antimicrob. Agents Chemother. 1997, 41:587-593.
5. Andrei G., Snoeck R., Piette J., Delvenne P., De Clercq E. Antiproliferative effects of acyclic nucleoside phosphonates on human papillomavirus (HPV)-harboring cell lines compared with HPV-negative cell lines. Oncol. Res. 1998, 10:523-531.
6. Andrei G., Snoeck R., Piette J., Delvenne P., De Clercq E. Inhibiting effects of cidofovir (HPMPC) on the growth of the human cervical carcinoma (SiHa) xenografts in athymic nude mice. Oncol. Res. 1998, 10:533-539.
7. Andrei G., Snoeck R., De Clercq E., Esnouf R., Fiten P., Opdenakker G. Resistance of herpes simplex virus type 1 against different phosphonylmethoxyalkyl derivatives of purines and pyrimidines due to specific mutations in the viral DNA polymerase gene. J. Gen. Virol. 2000, 81:639-648.
8. Andrei G., Gammon D.B., Fiten P., De Clercq E., Opdenakker G., Snoeck R., Evans D.H. Cidofovir resistance in vaccinia virus is linked to diminished virulence in mice. J. Virol. 2006, 80:9391-9401.
9. Andrei G., Fiten P., Froeyen M., De Clercq E., Opdenakker G., Snoeck R. DNA polymerase mutations in drug-resistant herpes simplex virus mutants determine in vivo neurovirulence and drug-enzyme interactions. Antivir. Ther. 2007, 12:719-732.
10. Bachmeyer C., Moguelet P., Baud F., Lescure F.X. Efflorescence of facial molluscum contagiosum as a manifestation of immune reconstitution inflammatory syndrome in a patient with AIDS. Eur. J. Dermatol. 2009, 19:257-258.
11. Baker R.O., Bray M., Huggins J.W. Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections. Antiviral Res. 2003, 57:13-23.
12. Balzarini J., Holy A., Jindrich J., Naesens L., Snoeck R., Schols D., De Clercq E. Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphonomethoxypropyl)-2,6-diaminopurine. Antimicrob. Agents Chemother. 1993, 37:332-338.
13. Baxter K.F., Highet A.S. Topical cidofovir and cryotherapy-combination treatment for recalcitrant molluscum contagiosum in a patient with HIV infection. J. Eur. Acad. Dermatol. Venereol. 2004, 18:230-231.
14. Beadle J.R., Wan W.B., Ciesla S.L., Keith K.A., Hartline C., Kern E.R., Hostetler K.Y. Synthesis and antiviral evaluation of alkoxyalkyl derivatives of 9-(S)-(3-hydroxy-2-phosphonomethoxypropyl)adenine against cytomegalovirus and orthopoxviruses. J. Med. Chem. 2006, 49:2010-2015.
15. Becker M.N., Obraztsova M., Kern E.R., Quenelle D.C., Keith K.A., Prichard M.N., Luo M., Moyer R.W. Isolation and characterization of cidofovir resistant vaccinia viruses. Virol. J. 2008, 5:58.
16. Birkus G., Rejman D., Otmar M., Votruba I., Rosenberg I., Holy A. The substrate activity of (S)-9-[3-hydroxy-(2-phosphonomethoxy)propyl]adenine diphosphate toward DNA polymerases alpha, delta and epsilon. Antivir. Chem. Chemother. 2004, 15:23-33.
17. Bonnafous P., Boutolleau D., Naesens L., Deback C., Gautheret-Dejean A., Agut H. Characterization of a cidofovir-resistant HHV-6 mutant obtained by in vitro selection. Antiviral Res. 2008, 77:237-240.
18. Briand S., Milpied B., Navas D., Thomare P., Stalder J.F. 1% Topical cidofovir used as last alternative to treat viral infections. J. Eur. Acad. Dermatol. Venereol. 2008, 22:249-250.
19. Bronson J.J., Ghazzouli I., Hitchcock M.J.M., Webb R.R., Kern E.R., Martin J.C. Synthesis and antiviral activity of nucleotide analogues bearing the (S)-(3-hydroxy-2-phosphonylmethoxy)propyl moiety attached to adenine, guanine and cytosine. Nucleotide Analogues As Antiviral Agents 1989, 88-102. American Chemical Society, Washington, DC. J.C. Martin (Ed.).
20. Bronson J.J., Ho H.-T., De Boeck H., Woods K., Ghazzouli I., Martin J.C., Hitchcock M.J.M. Biochemical pharmacology of acyclic nucleotide analogues. Ann. NY Acad. Sci. 1990, 616:398-407.
21. Buller R.M., Owens G., Schriewer J., Melman L., Beadle J.R., Hostetler K.Y. Efficacy of oral active ether lipid analogs of cidofovir in a lethal mousepox model. Virology 2004, 318:474-481.
22. Cherrington J.M., Allen S.J., McKee B.H., Chen M.S. Kinetic analysis of the interaction between the diphosphate of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine, ddCTP, AZTTP, and FIAUTP with human DNA polymerases beta and gamma. Biochem. Pharmacol. 1994, 48:1986-1988.
23. Cherrington J.M., Fuller M.D., Mulato A.S., Allen S.J., Kunder S.C., Ussery M.A., Lesnikowski Z., Schinazi R.F., Sommadossi J.P., Chen M.S. Comparative kinetic analyses of interaction of inhibitors with Rauscher murine leukemia virus and human immunodeficiency virus reverse transcriptases. Antimicrob. Agents Chemother. 1996, 40:1270-1273.
24. Cihlar T., Chen M.S. Identification of enzymes catalyzing two-step phosphorylation of cidofovir and the effect of cytomegalovirus infection on their activities in host cells. Mol. Pharmacol. 1996, 50:1502-1510.
25. Cihlar T., Fuller M.D., Mulato A.S., Cherrington J.M. A point mutation in the human cytomegalovirus DNA polymerase gene selected in vitro by cidofovir confers a slow replication phenotype in cell culture. Virology 1998, 248:382-393.
26. Cihlar T., Ho E.S., Lin D.C., Mulato A.S. Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs. Nucleosides Nucleotides Nucleic Acids 2001, 20:641-648.
27. Collette D.C., Zechel M.A. Novel treatment of atypical human papillomavirus-associated epithelial hyperplasia with cidofovir. J. Oral Maxillofac. Surg. 2011, 69:2383-2386.
28. Connelly M.C., Robbins B.L., Fridland A. Mechanism of uptake of the phosphonate analog (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) in Vero cells. Biochem. Pharmacol. 1993, 46:1053-1057.
29. Cundy K.C. Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir. Clin. Pharmacokinet. 1999, 36:127-143.
30. Dal Pozzo F., Andrei G., Lebeau I., Beadle J.R., Hostetler K.Y., De Clercq E., Snoeck R. In vitro evaluation of the anti-orf virus activity of alkoxyalkyl esters of CDV, cCDV and (S)-HPMPA. Antiviral Res. 2007, 75:52-57.
31. Davies E.G., Thrasher A., Lacey K., Harper J. Topical cidofovir for severe molluscum contagiosum. Lancet 1999, 353:2042.
32. De Clercq E. Acyclic nucleoside phosphonates in the chemotherapy of DNA virus and retrovirus infections. Intervirology 1997, 40:295-303.
33. De Clercq E. The acyclic nucleoside phosphonates from inception to clinical use: historical perspective. Antiviral Res. 2007, 75:1-13.
34. De Clercq E. The clinical potential of the acyclic (and cyclic) nucleoside phosphonates. The magic of the phosphonate bond. Biochem. Pharmacol. 2011, 82:99-109.
35. De Clercq E., Holy A. Acyclic nucleoside phosphonates: a key class of antiviral drugs. Nat. Rev. Drug Discov. 2005, 4:928-940.
36. De Clercq E., Neyts J. Antiviral agents acting as DNA or RNA chain terminators. Handb. Exp. Pharmacol. 2009, 53-84.
37. De Clercq E., Holy A., Rosenberg I., Sakuma T., Balzarini J., Maudgal P.C. A novel selective broad-spectrum anti-DNA virus agent. Nature 1986, 323:464-467.
38. De Clercq E., Sakuma T., Baba M., Pauwels R., Balzarini J., Rosenberg I., Holy A. Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines. Antiviral Res. 1987, 8:261-272.
39. Domaoal R.A., McMahon M., Thio C.L., Bailey C.M., Tirado-Rives J., Obikhod A., Detorio M., Rapp K.L., Siliciano R.F., Schinazi R.F., Anderson K.S. Pre-steady-state kinetic studies establish entecavir 5'-triphosphate as a substrate for HIV-1 reverse transcriptase. J. Biol. Chem. 2008, 283:5452-5459.
40. Duraffour S., Snoeck R., Krecmerova M., van Den Oord J., De Vos R., Holy A., Crance J.M., Garin D., De Clercq E., Andrei G. Activities of several classes of acyclic nucleoside phosphonates against camelpox virus replication in different cell culture models. Antimicrob. Agents Chemother. 2007, 51:4410-4419.
41. Duraffour S., Andrei G., Topalis D., Krečmerová M., Crance J.-M., Garin D., Snoeck R. Mutations conferring resistance to viral DNA polymerase inhibitors in camelpox virus give different drug-susceptibility profiles in vaccinia virus. J. Virol. 2012, 86:7310-7325.
42. Flores-Aguilar M., Huang J.-S., Wiley C.A., De Clercq E., Vuong C., Bergeron-Lynn G., Chandler B., Munguia D., Freeman W.R. Long-acting therapy of viral retinitis with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine. J. Infect. Dis. 1994, 169:642-647.
43. Frangeul A., Bussetta C., Deval J., Barral K., Alvarez K., Canard B. Gln151 of HIV-1 reverse transcriptase acts as a steric gate towards clinically relevant acyclic phosphonate nucleotide analogues. Antiviral Ther. 2008, 13:115-124.
44. Gammon D.B., Evans D.H. The 3'-to-5' exonuclease activity of vaccinia virus DNA polymerase is essential and plays a role in promoting virus genetic recombination. J. Virol. 2009, 83:4236-4250.
45. Gammon D.B., Snoeck R., Fiten P., Krecmerova M., Holy A., De Clercq E., Opdenakker G., Evans D.H., Andrei G. Mechanism of antiviral drug resistance of vaccinia virus: identification of residues in the viral DNA polymerase conferring differential resistance to antipoxvirus drugs. J. Virol. 2008, 82:12520-12534.
46. Gil-Fernandez C., Garcia-Villalon D., De Clercq E., Rosenberg I., Holy A. Phosphonylmethoxyalkylpurines and -pyrimidines as inhibitors of African swine fever virus replication in vitro. Antiviral Res. 1987, 8:273-281.
47. Gordon Y.J., Romanowski E., Araullo-Cruz T., Seaberg L., Erzurum S., Tolman R., De Clercq E. Inhibitory effect of (S)-HPMPC, (S)-HPMPA, and 2'-nor-cyclic GMP on clinical ocular adenoviral isolates is serotype-dependent in vitro. Antiviral Res. 1991, 16:11-16.
48. Gordon Y.J., Araullo-Cruz T.P., Johnson Y.F., Romanowski E.G., Kinchington P.R. Isolation of human adenovirus type 5 variants resistant to the antiviral cidofovir. Invest. Ophthalmol. Vis. Sci. 1996, 37:2774-2778.
49. Hartline C.B., Gustin K.M., Wan W.B., Ciesla S.L., Beadle J.R., Hostetler K.Y., Kern E.R. Ether lipid-ester prodrugs of acyclic nucleoside phosphonates: activity against adenovirus replication in vitro. J. Infect. Dis. 2005, 191:396-399.
50. Heijtink R.A., Kruining J., de Wilde G.A., Balzarini J., de Clercq E., Schalm S.W. Inhibitory effects of acyclic nucleoside phosphonates on human hepatitis B virus and duck hepatitis B virus infections in tissue culture. Antimicrob. Agents Chemother. 1994, 38:2180-2182.
51. Ho H.T., Woods K.L., Bronson J.J., De Boeck H., Martin J.C., Hitchcock M.J. Intracellular metabolism of the antiherpes agent (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine. Mol. Pharmacol. 1992, 41:197-202.
52. Hostetler K.Y., Aldern K.A., Wan W.B., Ciesla S.L., Beadle J.R. Alkoxyalkyl esters of (S)-9-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine are potent inhibitors of the replication of wild-type and drug-resistant human immunodeficiency virus type 1 in vitro. Antimicrob. Agents Chemother. 2006, 50:2857-2859.
53. Ibarra V., Blanco J.R., Oteo J.A., Rosel L. Efficacy of cidofovir in the treatment of recalcitrant molluscum contagiosum in an AIDS patient. Acta Derm. Venereol. 2000, 80:315-316.
54. Jesus D.M., Costa L.T., Goncalves D.L., Achete C.A., Attias M., Moussatche N., Damaso C.R. Cidofovir inhibits genome encapsidation and affects morphogenesis during the replication of vaccinia virus. J. Virol. 2009, 83:11477-11490.
55. Jiang Z.G., Cohen J., Marshall L.J., Major E.O. Hexadecyloxypropyl-cidofovir (CMX001) suppresses JC virus replication in human fetal brain SVG cell cultures. Antimicrob. Agents Chemother. 2010, 54:4723-4732.
56. Johnson J.A., Gangemi J.D. Selective inhibition of human papillomavirus-induced cell proliferation by (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine. Antimicrob. Agents Chemother. 1999, 43:1198-1205.
57. Julien O., Beadle J.R., Magee W.C., Chatterjee S., Hostetler K.Y., Evans D.H., Sykes B.D. Solution structure of a DNA duplex containing the potent anti-poxvirus agent cidofovir. J. Am. Chem. Soc. 2011, 133:2264-2274.
58. Keith K.A., Wan W.B., Ciesla S.L., Beadle J.R., Hostetler K.Y., Kern E.R. Inhibitory activity of alkoxyalkyl and alkyl esters of cidofovir and cyclic cidofovir against orthopoxvirus replication in vitro. Antimicrob. Agents Chemother. 2004, 48:1869-1871.
59. Kern E.R., Hartline C., Harden E., Keith K., Rodriguez N., Beadle J.R., Hostetler K.Y. Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir. Antimicrob. Agents Chemother. 2002, 46:991-995.
60. Kinchington P.R., Araullo-Cruz T., Vergnes J.P., Yates K., Gordon Y.J. Sequence changes in the human adenovirus type 5 DNA polymerase associated with resistance to the broad spectrum antiviral cidofovir. Antiviral Res. 2002, 56:73-84.
61. Kornbluth R.S., Smee D.F., Sidwell R.W., Snarsky V., Evans D.H., Hostetler K.Y. Mutations in the E9L polymerase gene of cidofovir-resistant vaccinia virus strain WR are associated with the drug resistance phenotype. Antimicrob. Agents Chemother. 2006, 50:4038-4043.
62. Kramata P., Votruba I., Otova B., Holy A. Different inhibitory potencies of acyclic phosphonomethoxyalkyl nucleotide analogs toward DNA polymerases alpha, delta and epsilon. Mol. Pharmacol. 1996, 49:1005-1011.
63. Lebeau I., Andrei G., Dal Pozzo F., Beadle J.R., Hostetler K.Y., De Clercq E., van den Oord J., Snoeck R. Activities of alkoxyalkyl esters of cidofovir (CDV), cyclic CDV, and (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine against orthopoxviruses in cell monolayers and in organotypic cultures. Antimicrob. Agents Chemother. 2006, 50:2525-2529.
64. Liekens S., Andrei G., Vandeputte M., De Clercq E., Neyts J. Potent inhibition of hemangioma formation in rats by the acyclic nucleoside phosphonate analogue cidofovir. Cancer Res. 1998, 58:2562-2567.
65. Liekens S., Neyts J., De Clercq E., Verbeken E., Ribatti D., Presta M. Inhibition of fibroblast growth factor-2-induced vascular tumor formation by the acyclic nucleoside phosphonate cidofovir. Cancer Res. 2001, 61:5057-5064.
66. Liekens S., Verbeken E., De Clercq E., Neyts J. Potent inhibition of hemangiosarcoma development in mice by cidofovir. Int. J. Cancer 2001, 92:161-167.
67. Lin J.C., De Clercq E., Pagano J.S. Inhibitory effects of acyclic nucleoside phosphonate analogs, including (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine, on Epstein-Barr virus replication. Antimicrob. Agents Chemother. 1991, 35:2440-2443.
68. Magee W.C., Hostetler K.Y., Evans D.H. Mechanism of inhibition of vaccinia virus DNA polymerase by cidofovir diphosphate. Antimicrob. Agents Chemother. 2005, 49:3153-3162.
69. Magee W.C., Aldern K.A., Hostetler K.Y., Evans D.H. Cidofovir and (S)-9-[3-hydroxy-(2-phosphonomethoxy)propyl]adenine are highly effective inhibitors of vaccinia virus DNA polymerase when incorporated into the template strand. Antimicrob. Agents Chemother. 2008, 52:586-597.
70. Magee W.C., Valiaeva N., Beadle J.R., Richman D.D., Hostetler K.Y., Evans D.H. Inhibition of HIV-1 by octadecyloxyethyl esters of (S)-[3-hydroxy-2-(phosphonomethoxy)propyl] nucleosides and evaluation of their mechanism of action. Antimicrob. Agents Chemother. 2011, 55:5063-5072.
71. Meadows K.P., Tyring S.K., Pavia A.T., Rallis T.M. Resolution of recalcitrant molluscum contagiosum virus lesions in human immunodeficiency virus-infected patients treated with cidofovir. Arch. Dermatol. 1997, 133:987-990.
72. Merta A., Votruba I., Rosenberg I., Otmar M., Hrebabecky H., Bernaerts R., Holy A. Inhibition of herpes simplex virus DNA polymerase by diphosphates of acyclic phosphonylmethoxyalkyl nucleotide analogues. Antiviral Res. 1990, 13:209-218.
73. Merta A., Votruba I., Jindrich J., Holy A., Cihlar T., Rosenberg I., Otmar M., Herve T.Y. Phosphorylation of 9-(2-phosphonomethoxyethyl)adenine and 9-(S)-(3-hydroxy-2-phosphonomethoxypropyl)adenine by AMP(dAMP) kinase from L1210 cells. Biochem. Pharmacol. 1992, 44:2067-2077.
74. Morrey J.D., Korba B.E., Beadle J.R., Wyles D.L., Hostetler K.Y. Alkoxyalkyl esters of 9-(s)-(3-hydroxy-2-phosphonomethoxypropyl) adenine are potent and selective inhibitors of hepatitis B virus (HBV) replication in vitro and in HBV transgenic mice in vivo. Antimicrob. Agents Chemother. 2009, 53:2865-2870.
75. Mul Y.M., van Miltenburg R.T., De Clercq E., van der Vliet P.C. Mechanism of inhibition of adenovirus DNA replication by the acyclic nucleoside triphosphate analogue (S)-HPMPApp influence of the adenovirus DNA binding protein. Nucleic Acids Res. 1989, 17:8917-8929.
76. Naesens L., Lenaerts L., Andrei G., Snoeck R., Van Beers D., Holy A., Balzarini J., De Clercq E. Antiadenovirus activities of several classes of nucleoside and nucleotide analogues. Antimicrob. Agents Chemother. 2005, 49:1010-1016.
77. Naesens L., Bonnafous P., Agut H., De Clercq E. Antiviral activity of diverse classes of broad-acting agents and natural compounds in HHV-6-infected lymphoblasts. J. Clin. Virol. 2006, 37(Suppl 1):S69-75.
78. Neyts J., De Clercq E. Antiviral drug susceptibility of human herpesvirus 8. Antimicrob. Agents Chemother. 1997, 41:2754-2756.
79. Okleberry K.M., Warren R.P., Smee D.F. Metabolism of ganciclovir and cidofovir in cells infected with drug-resistant and wild-type strains of murine cytomegalovirus. Antiviral Res. 1997, 35:83-90.
80. Painter G.R., Hostetler K.Y. Design and development of oral drugs for the prophylaxis and treatment of smallpox infection. Trends Biotechnol. 2004, 22:423-427.
81. Palú G., Stefanelli S., Rassu M., Parolin C., Balzarini J., De Clercq E. Cellular uptake of phosphonylmethoxyalkylpurine derivatives. Antiviral Res. 1991, 16:115-119.
82. Pauwels R., Balzarini J., Schols D., Baba M., Desmyter J., Rosenberg I., Holy A., De Clercq E. Phosphonylmethoxyethyl purine derivatives, a new class of anti-human immunodeficiency virus agents. Antimicrob. Agents Chemother. 1988, 32:1025-1030.
83. Quenelle D.C., Collins D.J., Kern E.R. Efficacy of multiple- or single-dose cidofovir against vaccinia and cowpox virus infections in mice. Antimicrob. Agents Chemother. 2003, 47:3275-3280.
84. Quenelle D.C., Collins D.J., Wan W.B., Beadle J.R., Hostetler K.Y., Kern E.R. Oral treatment of cowpox and vaccinia virus infections in mice with ether lipid esters of cidofovir. Antimicrob. Agents Chemother. 2004, 48:404-412.
85. Quenelle D.C., Collins D.J., Herrod B.P., Keith K.A., Trahan J., Beadle J.R., Hostetler K.Y., Kern E.R. Effect of oral treatment with hexadecyloxypropyl-[(S)-9-(3-hydroxy-2- phosphonylmethoxypropyl)adenine] [(S)-HPMPA] or octadecyloxyethyl-(S)-HPMPA on cowpox or vaccinia virus infections in mice. Antimicrob. Agents Chemother. 2007, 51:3940-3947.
86. Redondo P., Idoate M., Galofre J.C., Solano T. Cidofovir inhibits growth of B16 melanoma cells in vivo. Br. J. Dermatol. 2000, 143:741-748.
87. Reymen D., Naesens L., Balzarini J., Holy A., Dvorakova H., De Clercq E. Antiviral activity of selected acyclic nucleoside analogues against human herpesvirus 6. Antiviral Res. 1995, 28:343-357.
88. Scott G.M., Weinberg A., Rawlinson W.D., Chou S. Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates. Antimicrob. Agents Chemother. 2007, 51:89-94.
89. Shamoo Y., Steitz T.A. Building a replisome from interacting pieces: sliding clamp complexed to a peptide from DNA polymerase and a polymerase editing complex. Cell 1999, 99:155-166.
90. Sherman M.D., Feldman K.A., Farahmand S.M., Margolis T.P. Treatment of conjunctival squamous cell carcinoma with topical cidofovir. Am. J. Ophthalmol. 2002, 134:432-433.
91. Shigeta S., Konno K., Baba M., Yokota T., De Clercq E. Comparative inhibitory effects of nucleoside analogues on different clinical isolates of human cytomegalovirus in vitro. J. Infect. Dis. 1991, 163:270-275.
92. Smee D.F., Bailey K.W., Wong M.-H., Sidwell R.W. Intranasal treatment of cowpox virus respiratory infections in mice with cidofovir. Antiviral Res. 2000, 47:171-177.
93. Smee D.F., Sidwell R.W., Kefauver D., Bray M., Huggins J.W. Characterization of wild-type and cidofovir-resistant strains of camelpox, cowpox, monkeypox, and vaccinia viruses. Antimicrob. Agents Chemother. 2002, 46:1329-1335.
94. Smee D.F., Wandersee M.K., Bailey K.W., Hostetler K.Y., Holy A., Sidwell R.W. Characterization and treatment of cidofovir-resistant vaccinia (WR strain) virus infections in cell culture and in mice. Antivir. Chem. Chemother. 2005, 16:203-211.
95. Smith I.L., Taskintuna I., Rahhal F.M., Powell H.C., Ai E., Mueller A.J., Spector S.A., Freeman W.R. Clinical failure of CMV retinitis with intravitreal cidofovir is associated with antiviral resistance. Arch. Ophthalmol. 1998, 116:178-185.
96. Snoeck R., Sakuma T., De Clercq E., Rosenberg I., Holy A. (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine, a potent and selective inhibitor of human cytomegalovirus replication. Antimicrob. Agents Chemother. 1988, 32:1839-1844.
97. Snoeck R., Andrei G., De Clercq E. Patterns of resistance and sensitivity to antiviral compounds of drug-resistant strains of human cytomegalovirus selected in vitro. Eur. J. Clin. Microbiol. Infect. Dis. 1996, 15:574-579.
98. Snoeck R., Noel J.C., Muller C., De Clercq E., Bossens M. Cidofovir, a new approach for the treatment of cervix intraepithelial neoplasia grade III (CIN III). J. Med. Virol. 2000, 60:205-209.
99. Spanos W.C., El-Deiry M., Lee J.H. Cidofovir incorporation into human keratinocytes with episomal HPV 16 results in nonselective cytotoxicity. Ann. Otol. Rhinol. Laryngol. 2005, 114:840-846.
100. Srinivas R.V., Connely M., Fridland A. (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) inhibits HIV-1 replication in epithelial cells, but not T-lymphocytes. Antiviral Res. 1997, 35:23-27.
101. Talmon G., Cornell L.D., Lager D.J. Mitochondrial changes in cidofovir therapy for BK virus nephropathy. Transplant Proc. 2010, 42:1713-1715.
102. Tchesnokov E.P., Obikhod A., Schinazi R.F., Gotte M. Delayed chain termination protects the anti-hepatitis B virus drug entecavir from excision by HIV-1 reverse transcriptase. J. Biol. Chem. 2008, 283:34218-34228.
103. Terry B.J., Mazina K.E., Tuomari A.V., Haffey M.L., Hagen M., Feldman A., Slusarchyk W.A., Young M.G., Zahler R., Field A.K. Broad-spectrum antiviral activity of the acyclic guanosine phosphonate (R, S)-HPMPG. Antiviral Res. 1988, 10:235-251.
104. Topalis D., Lebeau I., Krecmerova M., Andrei G., Snoeck R. Activities of different classes of acyclic nucleoside phosphonates against BK virus in primary human renal cells. Antimicrob. Agents Chemother. 2011, 55:1961-1967.
105. Toro J.R., Wood L.V., Patel N.K., Turner M.L. Topical cidofovir: a novel treatment for recalcitrant molluscum contagiosum in children infected with human immunodeficiency virus 1. Arch. Dermatol. 2000, 136:983-985.
106. Valiaeva N., Prichard M.N., Buller R.M., Beadle J.R., Hartline C.B., Keith K.A., Schriewer J., Trahan J., Hostetler K.Y. Antiviral evaluation of octadecyloxyethyl esters of (S)-3-hydroxy-2-(phosphonomethoxy)propyl nucleosides against herpesviruses and orthopoxviruses. Antiviral Res. 2009, 84:254-259.
107. Vesely J., Merta A., Votruba I., Rosenberg I., Holy A. The cytostatic effects and mechanism of action of antiviral acyclic adenine nucleotide analogs in L1210 mouse leukemia cells. Neoplasma 1990, 37:105-110.
108. Votruba I., Bernaerts R., Sakuma T., De Clercq E., Merta A., Rosenberg I., Holy A. Intracellular phosphorylation of broad-spectrum anti-DNA virus agent (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine and inhibition of viral DNA synthesis. Mol. Pharmacol. 1987, 32:524-529.
109. Watanabe T., Tamaki K. Cidofovir diphosphate inhibits molluscum contagiosum virus DNA polymerase activity. J. Invest. Dermatol. 2008, 128:1327-1329.
110. Wyles D.L., Patel A., Madinger N., Bessesen M., Krause P.R., Weinberg A. Development of herpes simplex virus disease in patients who are receiving cidofovir. Clin. Infect. Dis. 2005, 41:676-680.
111. Wyles D.L., Kaihara K.A., Korba B.E., Schooley R.T., Beadle J.R., Hostetler K.Y. The octadecyloxyethyl ester of (S)-9-[3-hydroxy-2-(phosphonomethoxy) propyl]adenine is a potent and selective inhibitor of hepatitis C virus replication in genotype 1A, 1B, and 2A replicons. Antimicrob. Agents Chemother. 2009, 53:2660-2662.
112. Xiong X., Smith J.L., Kim C., Huang E.S., Chen M.S. Kinetic analysis of the interaction of cidofovir diphosphate with human cytomegalovirus DNA polymerase. Biochem. Pharmacol. 1996, 51:1563-1567.
113. Xiong X., Smith J.L., Chen M.S. Effect of incorporation of cidofovir into DNA by human cytomegalovirus DNA polymerase on DNA elongation. Antimicrob. Agents Chemother. 1997, 41:594-599.
114. Yokota T., Konno K., Chonan E., Mochizuki S., Kojima K., Shigeta S., de Clercq E. Comparative activities of several nucleoside analogs against duck hepatitis B virus in vitro. Antimicrob. Agents Chemother. 1990, 34:1326-1330.
115. Yokota T., Mochizuki S., Konno K., Mori S., Shigeta S., De Clercq E. Inhibitory effects of selected antiviral compounds on human hepatitis B virus DNA synthesis. Antimicrob. Agents Chemother. 1991, 35:394-397.
116. Yoshida M., Yamada M., Tsukazaki T., Chatterjee S., Lakeman F.D., Nii S., Whitley R.J. Comparison of antiviral compounds against human herpesvirus 6 and 7. Antiviral Res. 1998, 40:73-84.
117. Yoshizaki T., Wakisaka N., Kondo S., Murono S., Shimizu Y., Nakashima M., Tsuji A., Furukawa M. Treatment of locally recurrent Epstein-Barr virus-associated nasopharyngeal carcinoma using the anti-viral agent cidofovir. J. Med. Virol. 2008, 80:879-882.
118. Yu K.L., Bronson J.J., Yang H., Patick A., Alam M., Brankovan V., Datema R., Hitchcock M.J., Martin J.C. Synthesis and antiviral activity of methyl derivatives of 9-[2-(phosphonomethoxy)ethyl]guanine. J. Med. Chem. 1992, 35:2958-2969.
119. Zabawski E.J., Cockerell C.J. Topical cidofovir for molluscum contagiosum in children. Pediatr. Dermatol. 1999, 16:414-415.
120. Zhang Y., Schols D., De Clercq E. Selective activity of various antiviral compounds against HHV-7 infection. Antiviral Res. 1999, 43:23-35.